본문

  1. Home
5 Results:AA:MCCLUNG M PP:ELSEVIER INC 0.265 sec.
RSS 
Multilingual
 Recherche avancée
 nouvelle arrivée Rechercher
impression sélectionné Select Export to Excel
1
Do current management strategies and guidelines adequately address fracture risk?
Do current management strategies and guidelines adequately address fracture risk?
McClung, M. R., | Elsevier Inc | 2006 ,
2
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Pierre D Delmas,, | Elsevier Inc | 2008 ,
3
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
McClung, M. R., | Elsevier Inc | 2009 ,
4
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
McClung, M., | Elsevier Inc | 2007 ,
5
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Miller, P. D, | Elsevier Inc | 2008 ,
처음1마지막